Healthcare Review: BioMarin Pharmaceutical, InterMune, Amicus Therapeutics, Pharmacyclics Are Notable Movers Print E-mail
By Staff and Wire Reports   
Monday, 05 November 2012 15:21
The Dow and the S&P 500 edged lower in light trading on Monday, a day before the U.S. presidential election as traders were reluctant to take positions until the winner of the close race is known.

Democratic President Barack Obama and his challenger, Republican Mitt Romney, dashed through a handful of swing states, stumping for votes on the last day of the campaign for the White House.

Following are the notable movers at mad day on Monday.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
shares gained 28.47% to $48.08. The company said a Phase 3 study of its enzyme replacement therapy, GALNS, showed it improved the six-minute walking distance for patients with the rare lysosomal storage disorder mucopolysaccharidosis type IVA. People with MPS IVA, also called Morquio A Syndrome, have an enzyme deficiency that can cause growth retardation, knees that are abnormally close together, flat feet and other abnormalities.

InterMune, Inc. (NASDAQ:ITMN)
stock increased 6.88% to $8.39. The company announced that it will release its third quarter and first nine months 2012 financial results at the close of the U.S. markets on Wednesday, November 7, 2012.  A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

Amicus Therapeutics, Inc. (NASDAQ:FOLD)
stock jumped 5.80% to $5.29. The company announced updated data from an open-label, Phase 2 extension study (Study 205/FAB-CL-205) to investigate the long-term safety, tolerability and pharmacodynamics of migalastat HCl in 23 patients with Fabry disease who completed an initial Phase 2 study. Amicus in collaboration with GlaxoSmithKline (GSK) is developing the investigational pharmacological chaperone Migalastat HCl for the treatment of Fabry disease. Results1 from Study 205 were presented at the American Society of Nephrology (ASN) Kidney Week 2012.

EXACT Sciences Corporation (NASDAQ:EXAS) shares climbed 5.76% to $9.55. The company reported total revenues of $1.0 million for the third quarter of 2012 and the third quarter of 2011. Total revenues for each of the nine-months ended Sept. 30, 2012, and Sept 30, 2011, were $3.1 million. The company reported a net loss of ($13.0) million, or ($0.21) a share, for the third quarter of 2012. The company had a net loss of ($7.8) million, or ($0.15) a share, for the same period of 2011. The net loss for the nine-month period ended Sept. 30, 2012, was ($38.4) million, or ($0.66) a share. The company's net loss for the same period of 2011 was ($18.8) million, or ($0.36) a share.

Pharmacyclics, Inc. (NASDAQ:PCYC)
shares dropped 11.19% to $50.95 after the company reported first-quarter GAAP net income of $75.6 million, or $1.02 per share, as compared to GAAP net loss of $14.5 million, or $0.21 loss per share in the year ago quarter. The non-GAAP net income for the fiscal quarter was $78.8 million or $1.06 income per share, compared to a non-GAAP net loss of $12.4 million, or $0.18 per share last year. Revenue for the quarter was $102.7 million, compared to $37,000 last year, an increase of approximately $102.7 million. Analysts expected the company to report earnings of $0.75 per share on revenues of $87.64 million for the quarter.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus